Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > S&P Biotech ETF enters bull market up 29% in 13 trading days
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Jul 08, 2022 6:33pm
191 Views
Post# 34812210

RE:RE:RE:RE:RE:RE:RE:RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading days

RE:RE:RE:RE:RE:RE:RE:RE:RE:S&P Biotech ETF enters bull market up 29% in 13 trading days
Ronrydell,,,,,***I wish that the group of seven who all own in excess on one million shares would keep us in the loop as they should have some clout with Mgmt.***

My neighbor and myself together have upwards of 900,000 shares,,and we are just average retail shareholders/invetsors,,, I suspect the group of 7 you refer to,,who ever they are,,,,would dwarf us 10 or 20 fold~!!!,,,,,

Cuz they are probably more of the know,,,and,,,see BTI tooooo daahhhhhhh Moooooooooon sooner than later!!!

Wooohoooooo,,we have never been in such a good position  to make major advancements,,,,,,,,,!!,,Belly up to the trading post naysayers!!,,,you are going to embarrass yourselves!!!,,,,and of course,,,,,,,smoke 'em if you got 'em!!!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities